Sangamo Therapeutics Stock Performance
| SGMO Stock | USD 1.23 0.10 8.85% |
The entity has a beta of -1.49, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Sangamo Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Sangamo Therapeutics is expected to outperform it. Sangamo Therapeutics right now has a risk of 11.03%. Please validate Sangamo Therapeutics value at risk, as well as the relationship between the skewness and day median price , to decide if Sangamo Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sangamo Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy primary indicators, Sangamo Therapeutics is not utilizing all of its potentials. The newest stock price disarray, may contribute to short-term losses for the investors. ...more
1 | Beyond Air, Inc. Reports Q2 Loss, Lags Revenue Estimates | 11/11/2024 |
2 | Disposition of 7473 shares by Macrae Sandy of Sangamo Therapeutics at 1.88 subject to Rule 16b-3 | 11/22/2024 |
3 | Disposition of 10642 shares by Macrae Sandy of Sangamo Therapeutics at 1.94 subject to Rule 16b-3 | 11/25/2024 |
4 | Disposition of 5474 shares by Duraibabu Prathyusha of Sangamo Therapeutics at 1.13 subject to Rule 16b-3 | 12/13/2024 |
5 | Sangamo Therapeutics Receives Buy Rating from HC Wainwright | 12/20/2024 |
6 | Why Is Sangamo Therapeutics Inc. Among the Top CRISPR Stocks to Invest In | 12/30/2024 |
7 | Sangamo price target lowered by 1 at Wells Fargo, heres why SGMOPFE | 12/31/2024 |
8 | Securities Fraud Investigation Into Sangamo Therapeutics, Inc. Announced Investors Who Lost Money Urged To Contact Glancy Prongay Murray LLP, a Leading Securiti... | 01/02/2025 |
9 | Merck is a new year outlier with its diabetes drug | 01/03/2025 |
10 | WASATCH ADVISORS LP Reduces Stake in Sangamo Therapeutics Inc | 01/08/2025 |
11 | Disposition of 412584 shares by Macrae Sandy of Sangamo Therapeutics at 1.15 subject to Rule 16b-3 | 01/22/2025 |
| Begin Period Cash Flow | 101.9 M |
Sangamo |
Sangamo Therapeutics Relative Risk vs. Return Landscape
If you would invest 188.00 in Sangamo Therapeutics on November 1, 2024 and sell it today you would lose (65.00) from holding Sangamo Therapeutics or give up 34.57% of portfolio value over 90 days. Sangamo Therapeutics is currently generating 0.0516% in daily expected returns and assumes 11.0253% risk (volatility on return distribution) over the 90 days horizon. In different words, 98% of stocks are less volatile than Sangamo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sangamo Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sangamo Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sangamo Therapeutics, and traders can use it to determine the average amount a Sangamo Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0047
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | SGMO |
| Negative Returns |
Estimated Market Risk
| 11.03 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sangamo Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sangamo Therapeutics by adding Sangamo Therapeutics to a well-diversified portfolio.
Sangamo Therapeutics Fundamentals Growth
Sangamo Stock prices reflect investors' perceptions of the future prospects and financial health of Sangamo Therapeutics, and Sangamo Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sangamo Stock performance.
| Return On Equity | -1.94 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (94.13) % | ||||
| Current Valuation | 224.3 M | ||||
| Shares Outstanding | 208.22 M | ||||
| Price To Earning | (15.31) X | ||||
| Price To Book | 6.02 X | ||||
| Price To Sales | 4.51 X | ||||
| Revenue | 176.23 M | ||||
| Gross Profit | (138.6 M) | ||||
| EBITDA | (87.43 M) | ||||
| Net Income | (257.83 M) | ||||
| Cash And Equivalents | 315.72 M | ||||
| Cash Per Share | 2.02 X | ||||
| Total Debt | 38.1 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 2.86 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (224.84 M) | ||||
| Earnings Per Share | (1.24) X | ||||
| Market Capitalization | 563.24 M | ||||
| Total Asset | 165.32 M | ||||
| Retained Earnings | (1.41 B) | ||||
| Working Capital | 46.6 M | ||||
| Current Asset | 212.58 M | ||||
| Current Liabilities | 20.1 M | ||||
About Sangamo Therapeutics Performance
By examining Sangamo Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Sangamo Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Sangamo Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.79) | (1.70) | |
| Return On Capital Employed | (2.68) | (2.55) | |
| Return On Assets | (1.79) | (1.70) | |
| Return On Equity | (3.58) | (3.40) |
Things to note about Sangamo Therapeutics performance evaluation
Checking the ongoing alerts about Sangamo Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sangamo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sangamo Therapeutics had very high historical volatility over the last 90 days | |
| Sangamo Therapeutics may become a speculative penny stock | |
| Sangamo Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 176.23 M. Net Loss for the year was (257.83 M) with loss before overhead, payroll, taxes, and interest of (138.6 M). | |
| Sangamo Therapeutics currently holds about 315.72 M in cash with (224.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sangamo Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of 412584 shares by Macrae Sandy of Sangamo Therapeutics at 1.15 subject to Rule 16b-3 |
- Analyzing Sangamo Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sangamo Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Sangamo Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sangamo Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sangamo Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sangamo Therapeutics' stock. These opinions can provide insight into Sangamo Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.24) | Revenue Per Share | Quarterly Revenue Growth (0.95) | Return On Assets | Return On Equity |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.